EP4732015A1 - Méthode de diagnostic de la fibrose hépatique - Google Patents

Méthode de diagnostic de la fibrose hépatique

Info

Publication number
EP4732015A1
EP4732015A1 EP24735630.6A EP24735630A EP4732015A1 EP 4732015 A1 EP4732015 A1 EP 4732015A1 EP 24735630 A EP24735630 A EP 24735630A EP 4732015 A1 EP4732015 A1 EP 4732015A1
Authority
EP
European Patent Office
Prior art keywords
fibrosis
patient
patients
values
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24735630.6A
Other languages
German (de)
English (en)
Inventor
Thierry Poynard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biopredictive
Original Assignee
Biopredictive
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP23305987.2A external-priority patent/EP4481388A1/fr
Priority claimed from EP23305989.8A external-priority patent/EP4481390A1/fr
Priority claimed from EP23305988.0A external-priority patent/EP4481389A1/fr
Application filed by Biopredictive filed Critical Biopredictive
Publication of EP4732015A1 publication Critical patent/EP4732015A1/fr
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G01N33/723—Glycosylated haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/728—Bilirubin; including biliverdin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91188—Transferases (2.) transferring nitrogenous groups (2.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/02—Triacylglycerols
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un nouveau test quantitatif non invasif permettant de détecter la fibrose hépatique chez une personne atteinte du diabète de type 2 à l'aide de tests non invasifs sexospécifiques.
EP24735630.6A 2023-06-21 2024-06-20 Méthode de diagnostic de la fibrose hépatique Pending EP4732015A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP23305987.2A EP4481388A1 (fr) 2023-06-21 2023-06-21 Procédé de diagnostic de la stéatose hépatique
EP23305989.8A EP4481390A1 (fr) 2023-06-21 2023-06-21 Procédé de diagnostic de fibrose hépatique
EP23305988.0A EP4481389A1 (fr) 2023-06-21 2023-06-21 Procédé de diagnostic de l'hépatite stéatotique non alcoolique
PCT/EP2024/067360 WO2024261199A1 (fr) 2023-06-21 2024-06-20 Méthode de diagnostic de la fibrose hépatique

Publications (1)

Publication Number Publication Date
EP4732015A1 true EP4732015A1 (fr) 2026-04-29

Family

ID=91663885

Family Applications (3)

Application Number Title Priority Date Filing Date
EP24735977.1A Pending EP4732017A1 (fr) 2023-06-21 2024-06-20 Procédé de diagnostic de la stéatohépatite non alcoolique
EP24735976.3A Pending EP4732016A1 (fr) 2023-06-21 2024-06-20 Méthode de diagnostic de la stéatose hépatique
EP24735630.6A Pending EP4732015A1 (fr) 2023-06-21 2024-06-20 Méthode de diagnostic de la fibrose hépatique

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP24735977.1A Pending EP4732017A1 (fr) 2023-06-21 2024-06-20 Procédé de diagnostic de la stéatohépatite non alcoolique
EP24735976.3A Pending EP4732016A1 (fr) 2023-06-21 2024-06-20 Méthode de diagnostic de la stéatose hépatique

Country Status (2)

Country Link
EP (3) EP4732017A1 (fr)
WO (3) WO2024261197A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2420089C (fr) 2000-08-21 2009-04-14 Assistance Publique-Hopitaux De Paris Diagnostic de maladie fibrogene a l'aide de marqueurs biochimiques
WO2014049131A1 (fr) 2012-09-28 2014-04-03 Université d'Angers Test sanguin précis pour le diagnostic non invasif de la stéatohépatite non alcoolique
GB201614455D0 (en) 2016-08-24 2016-10-05 Univ Oxford Innovation Ltd Biomarkers
EP3296744A1 (fr) 2016-09-16 2018-03-21 Biopredictive Procédé de diagnostic de stéatoses hépatiques d'origine non alcoolique
EP3599615A1 (fr) 2018-07-27 2020-01-29 Biopredictive Procédé de diagnostic de la stéatose du foie

Also Published As

Publication number Publication date
EP4732017A1 (fr) 2026-04-29
WO2024261199A1 (fr) 2024-12-26
EP4732016A1 (fr) 2026-04-29
WO2024261197A1 (fr) 2024-12-26
WO2024261198A1 (fr) 2024-12-26

Similar Documents

Publication Publication Date Title
Long et al. AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review
Bril et al. Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes
Hagström et al. Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease
US20250306025A1 (en) Method of prognosis and follow up of primary liver cancer
Davison et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials
CN112805789B (zh) 诊断肝脂肪变性的方法
Vatsalya et al. Keratin 18 is a diagnostic and prognostic factor for acute alcoholic hepatitis
Hsu et al. Body mass index and risk for end-stage renal disease
Dowman et al. Systematic review: the diagnosis and staging of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis
Macedo et al. Oliguria is an early predictor of higher mortality in critically ill patients
Lahiff et al. The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome
Rossi et al. Assessing liver fibrosis with serum marker models
Mendoza et al. Inflammatory activity affects the accuracy of liver stiffness measurement by transient elastography but not by two‐dimensional shear wave elastography in non‐alcoholic fatty liver disease
EP3513193B1 (fr) Procédé de diagnostic de stéatoses hépatiques d'origine non alcoolique
Harrison et al. Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers
Ooi et al. Modified thresholds for fibrosis risk scores in nonalcoholic fatty liver disease are necessary in the obese
Shen et al. Vibration-controlled transient elastography for assessment of liver fibrosis at a USA academic medical center
Wan et al. Applicability and results of liver stiffness measurement and controlled attenuation parameter using XL probe for metabolic-associated fatty liver disease in candidates to bariatric surgery. A single-center observational study
Feng et al. A simpler diagnostic formula for screening nonalcoholic fatty liver disease
Gabriel-Medina et al. Accuracy of a sequential algorithm based on FIB-4 and ELF to identify high-risk advanced liver fibrosis at the primary care level
Lee et al. The prevalence of advanced liver fibrosis among patients with type 2 diabetes mellitus: a single-centre experience in penang, malaysia
Cho et al. Synergistic effect of non-alcoholic fatty liver disease and history of gestational diabetes to increase risk of type 2 diabetes
EP4481390A1 (fr) Procédé de diagnostic de fibrose hépatique
EP4481389A1 (fr) Procédé de diagnostic de l'hépatite stéatotique non alcoolique
EP4481388A1 (fr) Procédé de diagnostic de la stéatose hépatique

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251221

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR